NeuroScientific Biopharmaceuticals dosed a fourth Crohn’s patient with its StemSmart therapy ahead of phase 2 trials for its novel treatment of the debilitating bowel disease.
Business / Companies
Brisbane Times – Business
NeuroScientific Biopharmaceuticals dosed a fourth Crohn’s patient with its StemSmart therapy ahead of phase 2 trials for its novel treatment of the debilitating bowel disease.
Business / Companies
Brisbane Times – Business